AEZS.TO Stock - Aeterna Zentaris Inc.
Unlock GoAI Insights for AEZS.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $4.50M | $5.64M | $5.26M | $3.65M | $532,000 |
| Gross Profit | $4.28M | $5.48M | $5.17M | $1.33M | $122,000 |
| Gross Margin | 95.1% | 97.2% | 98.3% | 36.6% | 22.9% |
| Operating Income | $-18,008,000 | $-15,377,000 | $-8,671,000 | $-5,925,000 | $-9,544,000 |
| Net Income | $-3,550,349 | $3.24M | $2.64M | $1.46M | $-6,042,000 |
| Net Margin | -78.9% | 57.5% | 50.2% | 39.9% | -1135.7% |
| EPS | $-1.92 | $1.87 | $1.33 | $0.66 | $-8.75 |
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Visit WebsiteEarnings History & Surprises
AEZS.TOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 14, 2024 | $-1.11 | $-2.57 | -131.7% | ✗ MISS |
Q1 2024 | Mar 27, 2024 | $-0.97 | $-1.16 | -19.6% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.61 | $-0.85 | -39.3% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.87 | $-0.52 | +40.2% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-1.07 | $-0.88 | +17.8% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.93 | $-0.87 | +6.5% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.68 | $-0.70 | -2.9% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $-0.68 | $-0.87 | -27.9% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.50 | $-0.50 | 0.0% | = MET |
Q1 2022 | Mar 28, 2022 | $-0.50 | $-0.50 | 0.0% | = MET |
Q4 2021 | Nov 4, 2021 | $-0.50 | $-0.25 | +50.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | — | $-0.52 | — | — |
Q2 2021 | May 5, 2021 | — | $-0.48 | — | — |
Q1 2021 | Mar 25, 2021 | — | $-0.74 | — | — |
Q4 2020 | Nov 6, 2020 | — | $-0.67 | — | — |
Q3 2020 | Aug 8, 2020 | — | $-4.97 | — | — |
Q2 2020 | May 6, 2020 | — | $1.26 | — | — |
Q1 2020 | Mar 30, 2020 | — | $-0.05 | — | — |
Q4 2019 | Nov 8, 2019 | $-4.25 | $-0.50 | +88.2% | ✓ BEAT |
Q3 2019 | Aug 13, 2019 | $-3.50 | $0.25 | +107.1% | ✓ BEAT |
Latest News
Frequently Asked Questions about AEZS.TO
What is AEZS.TO's current stock price?
What is the analyst price target for AEZS.TO?
What sector is Aeterna Zentaris Inc. in?
What is AEZS.TO's market cap?
Does AEZS.TO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AEZS.TO for comparison